18 results
20-F/A
2023 FY
IPCIF
Intellipharmaceutics International Inc.
6 Feb 24
Annual report (foreign) (amended)
12:00am
, the FDA has developed an action plan and has committed to enhance safety labeling, require new data, strengthen post-market requirements, update
20-F/A
2021 FY
IPCIF
Intellipharmaceutics International Inc.
6 May 22
Annual report (foreign) (amended)
7:54pm
and are focusing on policies aimed at reversing the potential for abuse. In furtherance of those efforts, the FDA has developed an action plan and has
6-K
EX-99.1
IPCIF
Intellipharmaceutics International Inc.
28 Feb 22
Primary Document
9:56pm
efforts, the FDA has developed an action plan and has committed to enhance safety labeling, require new data, strengthen post-market requirements
6-K
EX-99.1
nt06s70 pjjb8lqdaz9g
1 Mar 21
Primary Document
8:21am
6-K
EX-99.1
8t3hlj
28 Feb 20
Primary Document
4:42pm
6-K
EX-99.1
cb0 pc6m0gk
4 Mar 19
Primary Document
7:13am
20-F/A
1fiws d86gzh5wrxdu
4 Mar 19
Annual report (foreign) (amended)
7:05am
6-K
EX-99.1
31i4k0pp 2xf
1 Mar 19
Primary Document
12:00am
424B4
yvnmlj9q
15 Oct 18
Prospectus supplement with pricing info
7:34am
F-1/A
sb71dg ny3l0j1
11 Oct 18
Registration statement (foreign) (amended)
6:41am
F-1/A
zy6aw7t
4 Oct 18
Registration statement (foreign) (amended)
9:47pm
F-1
5rtftjqt25 rpn2z
20 Sep 18
Registration statement (foreign)
5:24pm
- Prev
- 1
- Next